表纸
市场调查报告书

传染病分子诊断的全球市场:影响和预测,分析COVID-19,2021-2025

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021-2025

出版商 Howe Sound Research 商品编码 969250
出版日期 内容资讯 英文 445 Pages
商品交期: 最快1-2个工作天内
价格
传染病分子诊断的全球市场:影响和预测,分析COVID-19,2021-2025 Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2021-2025
出版日期: 2020年11月04日内容资讯: 英文 445 Pages
简介

本报告调查了全球传染病分子诊断市场,包括按疾病进行的市场分析,行业概况,主要公司的概况,市场趋势,最新趋势,全球市场概况,综合症,我们提供信息,例如按基因序列数量和测试位置进行分析。

此报告的关键字

<身体>
  • 生物标志物
  • 诊断
  • 分析
  • 体外诊断
  • 医学研究所
  • 体检
  • 体外诊断
  • 多重
  • 血液感染
  • 败血症
  • 性病
  • 性感染
  • 护理点
  • POC
  • DNA
  • RNA
  • 综合征
  • 呼吸
  • 胃肠道
  • 胃肠道
  • 肠胃炎
  • 脑膜炎
  • CNS
  • 中枢神经系统
  • mRNA
  • 转录组
  • 临床实验室
  • POL
  • 快速检查
  • 快速诊断
  • 临床实验室
  • COVID

目录

i。传染病的分子诊断-策略状况分析和COVID-19的影响

ii。高管,营销,销售和业务开发人员指南

iii。管理顾问和投资顾问指南

第1章市场介绍和定义

第2章按疾病进行的市场分析

  • HIV人免疫缺陷病毒(AIDS)
    • 病毒学
    • 诊断
    • 测试
    • 市场机会分析
  • HBV-B肝炎
    • 病毒学
    • 机制
    • 诊断
    • 市场机会分析
  • HCV-C肝炎
    • 分类方法
    • 结构
    • 分子生物学
    • 重复
    • 基因型
    • 市场机会分析
  • HPV人乳头瘤病毒
    • 病毒学
    • 诊断
    • 市场机会分析
  • 流感
    • 病毒学
    • 检验
    • 市场机会分析
  • CTGC-衣原体/山羊
    • 山羊
    • 衣原体
    • 检验
    • 市场机会分析
  • 肺结核
    • 分枝杆菌
    • 诊断
    • 流行病学
    • 分子诊断测试
    • 市场机会分析
  • MRSA-耐甲氧西林的黄色葡萄球菌
    • 诊断
    • FDA批准的分子测试
    • 市场机会分析
  • VRE-万古霉素耐药肠杆菌
    • FDA批准的VRE分子诊断测试
    • 市场机会分析
  • 血液筛查
    • 收集和检查
    • FDA批准的多元测定
    • 市场机会分析
  • COVID-19(新的冠状病毒感染)
    • 体征和症状
    • 感染
    • 诊断
    • 预防
    • 管理
    • 预后
  • 大流行诊断
    • 风险管理:感染迅速传播
    • 诊断技术:基于核酸
    • 诊断技术:免疫测定和血清学
    • 上市时间和准备工作问题
    • 多重传播在大流行管理中的作用尚未得到认识

第3章行业概述

  • 相关组织
    • 学术研究所
    • 诊断测试开发人员
    • 仪器供应商
    • 分销商和试剂供应商
    • 独立检查机构
    • 公共检查机构
    • 医院实验室
    • 临床实验室
    • 审计机构
    • 认证机构
  • 临床测试市场领域
  • 产业结构
  • 主要公司简介
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMrieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • Eiken Chemical
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

第4章市场趋势

  • 生长促进剂
  • 生长抑制剂
  • 仪表和自动化
  • 诊断技术的发展

第5章最新趋势

第6章世界市场

  • 各国市场概况
  • 按综合征分类的市场概况
  • 基因序列数量的市场概况
  • 检验地点的市场概况

第7章综合症市场

  • 呼吸
  • 胃肠道
  • 脑膜炎/脑炎
  • 性感染
  • 其他

第8章按基因序列数量划分的市场

  • 单重
  • 双工
  • 三层
  • 多重

第9章按检验地点划分的市场

  • 医院实验室
  • 门诊实验室
  • POC
  • 其他

附录

  • i。美国医疗保险制度:2020年临床检查费用表
  • II。批准的COVID-19分析
目录

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is a member of The American Association for Clinical Chemistry. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research - Burke Institute

Finance for Senior Executives - Harvard Business School

KEYWORDS for this report

  • biomarkers
  • diagnostic
  • assay
  • in vitro diagnostics
  • medical laboratory
  • medical tests
  • IVD
  • multiplex
  • blood infection
  • sepsis
  • STD
  • sexually transmitted
  • point of care
  • POC
  • DNA
  • RNA
  • syndrome
  • respiratory
  • GI
  • gastrointestinal
  • gastroenteritis
  • meningitis
  • CNS
  • central nervous system
  • mRNA
  • transcriptome
  • physician office lab
  • POL
  • rapid testing
  • rapid diagnostics
  • Clinical laboratory
  • COVID

Table of Contents

i. Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19.

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenues
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease

  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
    • 2.1.4 Market Opportunity Analysis
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
    • 2.3.2 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 Blood Screening
    • 2.10.1 Collection and Testing
    • 2.10.2 FDA Approved Multiplex Assays
    • 2.10.3 Market Opportunity Analysis
  • 2.11 COVID-19
    • 2.11.1 Signs and symptoms
    • 2.11.2 Transmission
    • 2.11.3 Diagnosis
    • 2.11.4 Prevention
    • 2.11.5 Management
    • 2.11.6 Prognosis
  • 2.12 Pandemic Diagnostics
    • 2.12.1 Risk Management - Spark and Spread
    • 2.12.2 Dx Technology - Nucleic Acid Based
    • 2.12.3 Dx Technology - Immunoassay & Serology
    • 2.12.4 Time to Market and Preparedness Issues
    • 2.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Distributor and Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Office Labs
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
      • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT
  • 3.4 Profiles of Key MDx Companies
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMérieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • Eiken Chemical
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 New Genotypes Creating New Markets
    • 4.1.2 Aging Population a Boon for All Diagnostics
    • 4.1.3 Developing World Driving ID Dx Growth
    • 4.1.4 Point of Care - Why Centralization is Losing Steam
    • 4.1.5 Self Testing
    • 4.1.6 The Need for Speed
    • 4.1.7 The COVID Pandemic
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Costs
    • 4.2.2 Infectious Disease is Declining
    • 4.2.3 Wellness Hurts
    • 4.2.4 Economic Growth improves Living Standards
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.2 Multiplex, Point of Care and The Speed Factor
  • 4.4 Diagnostic Technology Development
    • 4.4.1 The Sepsis Testing Market - A New Direction?
    • 4.4.2 POCT/Self Testing as a Disruptive Force
    • 4.4.3 The Genetics Play - One Test for All Known Infections
    • 4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

  • Recent Developments - Importance and How to Use This Section
    • Importance of These Developments
    • How to Use This Section
      • Scanogen Developing 90 Minute Infection Test
      • Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
      • FDA Provides Self Testing SARS-CoV-2 EAU Guidance
      • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
      • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
      • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
      • Lumos Diagnostics Closes $15M Series A Funding
      • Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
      • New Genomic Tests Diagnose Deadly Infections Faster
      • Biotia Raises $2.4M Seed Round
      • STDs resurge in US
      • Ares Genetics signs R&D agreement with leading global IVD corporation
      • Cell-Free DNA Used for Infectious Disease Testing
      • One BioMed Raises $5M
      • FDA grants Qiagen clearance for syndromic testing system
      • iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays
      • Researchers Launch CRISPR Dx Firm Sherlock Biosciences
      • Israel's BATM to Invest up to $30M in Ador Diagnostics
      • Superbug Test from Mobidiag Gets CE Mark
      • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
      • Mesa Biotech RSV Test Wins CE Mark
      • Karius Test to Be Available in Brazil
      • Panagene's STD kit gains Approval
      • Startup Prominex Raises $4M in Series A1
      • GenePOC's Investment Validated by Medicare Decision
      • GenePOC® launches its GenePOC® CDiff test in Canada
      • NYU researchers adapt HIV test to Zika virus
      • Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
      • Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
      • Ares Genetics to develop AI diagnostic test for infectious diseases

6. The Global Market for Molecular Diagnostics Infectious Disease

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Syndrome - Overview
    • 6.2.1 Table - Global Market by Syndrome
    • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Syndrome - Base Year
    • 6.2.4 Chart - Global Market by Syndrome - End Year
    • 6.2.5 Chart - Global Market by Syndrome - Share by Year
    • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Plex - Base Year
    • 6.3.4 Chart - Global Market by Plex - End Year
    • 6.3.5 Chart - Global Market by Plex - Share by Year
    • 6.3.6 Chart - Global Market by Plex - Segments Growth
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 6.4.3 Chart - Global Market by Place - Base Year
    • 6.4.4 Chart - Global Market by Place - End Year
    • 6.4.5 Chart - Global Market by Place - Share by Year
    • 6.4.6 Chart - Global Market by Place - Segments Growth

7. Global MDx Infectious Disease Markets - By Syndrome

  • 7.1 Respiratory
    • 7.1.1 Table Respiratory - by Country
    • 7.1.2 Chart - Respiratory Growth
  • 7.2 Gastrointestinal
    • 7.2.1 Table Gastrointestinal - by Country
    • 7.2.2 Chart - Gastrointestinal Growth
  • 7.3 Blood
    • 7.3.1 Table Blood - by Country
    • 7.3.2 Chart - Blood Growth
  • 7.4 Meningitis/Encephalitis
    • 7.4.1 Table Meningitis/Encephalitis - by Country
    • 7.4.2 Chart - Meningitis/Encephalitis Growth
  • 7.5 Sexually Transmitted Disease
    • 7.5.1 Table Sexually Transmitted Disease - by Country
    • 7.5.2 Chart - Sexually Transmitted Disease Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global MDx Markets for Infectious Disease - by Plex

  • 8.1 Single Plex
    • 8.1.1 Table Single Plex - by Country
    • 8.1.2 Chart - Single Plex Growth
  • 8.2 Duplex
    • 8.2.1 Table Duplex - by Country
    • 8.2.2 Chart - Duplex Growth
  • 8.3 Triplex
    • 8.3.1 Table Triplex - by Country
    • 8.3.2 Chart - Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global MDx Infectious Disease Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Classification of HIV Species
  • Table 3 HIV Tests - CMS Codes & Prices
  • Table 4 Current HIV Molecular Tests and Instruments Used
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 CTGC Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 FDA Approved Multiplex Assays
  • Table 23 Characteristics of Coronavirus Pandemic Infections
  • Table 24 COVID-19 Symptoms
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Five Factors Driving Growth
  • Table 30 Four Factors Limiting Growth
  • Table 31 Key Diagnostic Laboratory Technology Trends
  • Table 32 - Global Market by Region
  • Table 33 Global Market by Syndrome
  • Table 34 Global Market by Plex
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Single Plex by Country
  • Table 43 Duplex by Country
  • Table 44 Triplex by Country
  • Table 45 Multiplex by Country
  • Table 46 Hospital Lab by Country
  • Table 47 Outpatient Lab by Country
  • Table 48 POC by Country
  • Table 49 Other by Country
  • Table 50 2020 Clinical Lab Fee Schedule
  • Table 51 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 HIV Virion
  • Figure 3 Diagram of the HIV Replication Cycle
  • Figure 4 The Structure of the HBV Virus
  • Figure 5 Hepatitis B Replication
  • Figure 6 Structure of the HCV Virus
  • Figure 7 HCV Replication Cycle
  • Figure 8 Structure of the Influenza Virion
  • Figure 9 Influenza Replication
  • Figure 10 Scanning Electronmicrograph of Tuberculosis
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Chart Infectious Disease Decline
  • Figure 13 Global Market Shares Chart
  • Figure 14 Global Market by Syndrome - Base vs. Final
  • Figure 15 Global Market by Syndrome Base Year
  • Figure 16 Global Market by Syndrome End Year
  • Figure 17 Syndrome Share by Year
  • Figure 18 Syndrome Segments Growth
  • Figure 19 Global Market by Plex - Base vs. Final
  • Figure 20 Global Market by Plex Base Year
  • Figure 21 Global Market by Plex End Year
  • Figure 22 Plex Share by Year
  • Figure 23 Plex Segments Growth
  • Figure 24 Global Market by Place - Base vs. Final
  • Figure 25 Global Market by Place Base Year
  • Figure 26 Global Market by Place End Year
  • Figure 27 Place Share by Year
  • Figure 28 Place Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Gastrointestinal Diagnostics Growth
  • Figure 31 Blood Growth
  • Figure 32 Meningitis/Encephalitis Growth
  • Figure 33 Sexually Transmitted Disease Growth
  • Figure 34 Other Growth
  • Figure 35 Single Plex Growth
  • Figure 36 Duplex Growth
  • Figure 37 Triplex Growth
  • Figure 38 Multiplex Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 POC Growth
  • Figure 42 Other Growth